Bumetanide

ATC code

C03CA02

Therapeutic class

Loop diuretic · Sulfonamide, monocomponent

Forms

oral tablet, solution for injection

Brand names

FORDIURAN (ES) · Bumex (US) · Burinex (GB)

Overall confidence

medium

Regulatory sources consulted

Edema associated with congestive heart failure, liver cirrhosis, and renal disease, including nephrotic syndrome.

Major warning · Risk of profound diuresis with water and electrolyte depletion. Requires medical supervision and periodic monitoring of serum electrolytes. — AEMPS CIMA
Risk of ototoxicity, especially with high doses, rapid IV administration, or concomitant use of other ototoxic drugs. — AEMPS CIMA

HighLithiumN05AN01
Mechanism: Decreased renal clearance of lithium, increasing the risk of toxicity.
Recommendation: Avoid concomitant use. If necessary, monitor lithium levels closely and adjust dosage.
AEMPS CIMA FT 52047
HighAminoglycosidesJ01G
Mechanism: Increased potential for ototoxicity and nephrotoxicity.
Recommendation: Avoid concomitant use. If the combination is unavoidable, monitor auditory and renal function.
AEMPS CIMA FT 52047
ModerateNSAIDs (Nonsteroidal anti-inflammatory drugs)M01A
Mechanism: May reduce the diuretic and antihypertensive effect by inhibiting renal prostaglandin synthesis. Increases risk of renal failure.
Recommendation: Monitor blood pressure, diuresis, and renal function. Avoid in patients with pre-existing heart or renal failure.
AEMPS CIMA FT 52047

hypokalemia · hyponatremia · hyperuricemia · muscle cramps · dizziness · hypotension · headache

ototoxicity · acute renal failure · thrombocytopenia · agranulocytosis · hepatic encephalopathy

FDA category: C

Contraindicated during pregnancy and lactation according to the Spanish summary of product characteristics.